Product Information Sheet for NR-2654

Escherichia coli, Strain CFT073

Catalog No. NR-2654

(Derived from ATCC® 700928™)

For research use only. Not for human use.

Contributor:

Guy Plunkett, III, Ph.D., Laboratory of Genetics, University of Wisconsin-Madison, Madison, WI

Product Description:

Bacteria Classification: *Enterobacteriaceae, Escherichia*
Species: *Escherichia coli (E. coli)*
Strain: CFT073
Serotype: O6:H1:K2
Original Source:[1] *E. coli* CFT073 was originally obtained from the blood of a woman with acute pyelonephritis and was deposited by Dr. G. Plunkett in 2000
Comment: The complete genomic sequence of *E. coli,* strain CFT073 has been determined (5,231,430 bp; GenBank: AE014075)[2].

E. coli, strain CFT073 is a uropathogenic (UPEC) rod-shaped facultative anaerobe. It is one of the most common causes of non-hospital-acquired urinary tract infections. The uropathogenic *E. coli* differ from the diarrheal pathogens because they can behave as harmless human intestinal inhabitants or they can be serious pathogens when they enter the urinary tract and bloodstream. They have fimbrial operons as well as other virulence factors that allow colonization of the urinary tract.

Material Provided:

Each vial contains approximately 0.5 mL of bacterial culture in 0.5X Trypticase Soy Broth supplemented with 10% glycerol.

Packaging/Storage:

NR-2654 was packaged aseptically, in screw-capped plastic cryovials. The product is provided frozen and should be stored at -60°C or colder immediately upon arrival. For long-term storage, the vapor phase of a liquid nitrogen freezer is recommended. Freeze-thaw cycles should be avoided.

Growth Conditions:

Media:
Trypticase Soy Broth or equivalent
Trypticase Soy Agar or equivalent
Incubation:
Temperature: 37°C
Atmosphere: Aerobic
Propagation:

1. Keep vial frozen until ready for use; then thaw.
2. Transfer the entire thawed aliquot into a single tube of Trypticase Soy Broth.
3. Use several drops of the suspension to inoculate a Trypticase Soy Agar slant and/or plate.
4. Incubate the slant and/or plate at 37°C for 24 hours.

Citation:

Acknowledgment for publications should read "The following reagent was obtained through the NIH Biodefense and Emerging Infections Research Resources Repository, NIAID, NIH: *Escherichia coli*, Strain CFT073, NR-2654."

Biosafety Level: 2

Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the following publication: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, and National Institutes of Health. Biosafety in Microbiological and Biomedical Laboratories. 5th ed. Washington, DC: U.S. Government Printing Office, 2007; see www.cdc.gov/od/ohs/biosfty/bmbl5/bmbl5toc.htm.

Disclaimers:

You are authorized to use this product for research use only. It is not intended for human use.

Use of this product is subject to the terms and conditions of the BEI Resources Material Transfer Agreement (MTA). The MTA is available on our Web site at www.beiresources.org.

While BEI Resources uses reasonable efforts to include accurate and up-to-date information on this product sheet, neither ATCC® nor the U.S. Government make any warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. Neither ATCC® nor the U.S. Government warrants that such information has been confirmed to be accurate.

This product is sent with the condition that you are responsible for its safe storage, handling, use and disposal. ATCC® and the U.S. Government are not liable for any damages or injuries arising from receipt and/or use of this product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, the U.S. Government, ATCC®, their suppliers and contributors to BEI Resources are not liable for damages arising from the misidentification or misrepresentation of products.

Use Restrictions:

This material is distributed for internal research, non-commercial purposes only. This material, its product or its derivatives may not be distributed to third parties. Except as performed under a U.S. Government contract, individuals contemplating commercial use of the material, its products or its derivatives must contact the contributor to determine if a license is required. U.S. Government contractors may need a license before first commercial sale.

Biodefense and Emerging Infections Research Resources Repository
P.O. Box 4137
Manassas, VA 20108-4137 USA
www.beiresources.org
800-359-7370
Fax: 703-365-2898
E-mail: contact@beiresources.org

References:

1. Mobley, H. L., et al. "Pyelonephritogenic *Escherichia coli* and Killing of Cultured Human Renal Proximal Tubular Epithelial Cells: Role of Hemolysin in Some Strains." Infect. Immun. 58 (1990): 1281–1289. PubMed: 2182540.
2. Welch, R. A., et al. "Extensive Mosaic Structure Revealed by the Complete Genome Sequence of Uropathogenic *Escherichia coli*." Proc. Natl. Acad. Sci. U. S. A. 99 (2002): 17020–17024. PubMed: 12471157. GenBank: AE014075.
3. Durant, L., et al. "Identification of Candidates for a Subunit Vaccine against Extraintestinal Pathogenic *Escherichia coli*." Infect. Immun. 75 (2007): 1916–25. PubMed: 17145948.
4. Lloyd, A. L., D. A. Rasko, and H. L. Mobley. "Defining Genomic Islands and Uropathogen-Specific Genes in Uropathogenic *Escherichia coli*." J. Bacteriol. 189 (2007): 3532-3546. PubMed: 17351047.
5. Hancock, V. and P. Klemm. "Global Gene Expression Profiling of Asymptomatic Bacteriuria *Escherichia coli* during Biofilm Growth in Human Urine." Infect. Immun. 75 (2007): 966–976. PubMed: 17145952.
6. Brzuszkiewicz, E., et al. "How to Become a Uropathogen: Comparative Genomic Analysis of Extraintestinal Pathogenic *Escherichia coli* Strains." Proc. Natl. Acad. Sci. U. S. A. 103 (2006): 12879–12884. PubMed: 16912116.
7. Valle, J., et al. "Broad-Spectrum Biofilm Inhibition by a Secreted Bacterial Polysaccharide." Proc. Natl. Acad. Sci. U. S. A. 103 (2006): 12558–12563. PubMed: 16894146.
8. Sabate, M., et al. "Pathogenicity Island Markers in Commensal and Uropathogenic *Escherichia coli* Isolates." Clin. Microbiol. Infect. 12 (2006): 880–886. PubMed: 16882293.
9. Lane, M. C., et al. "Role of Motility in the Colonization of Uropathogenic *Escherichia coli* in the Urinary Tract." Infect. Immun. 73 (2005): 7644–7656. PubMed: 16239569.

Support Provided by NIAID

Biodefense and Emerging Infections Research Resources Repository
P.O. Box 4137
Manassas, VA 20108-4137 USA
www.beiresources.org

800-359-7370
Fax: 703-365-2898
E-mail: contact@beiresources.org